more energy on semaglutide Does Boost During Weight Loss? Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),
Description
Current annual therapy cost: ~1.51.7 lakh per patient At 5060% lower pricing: ~70,00085,000 per year Savings of nearly 80,0001,00,000 per patient annually Now consider scale: 100,000 patients 75,000 750 crore annual market 500,000 patients (just ~0.5% of high-risk obese population) 3,750 crore opportunity And thats only drug revenue
Clinical trials assessing GLP-1 RAs for weight loss rarely report facial fat loss as an adverse effect
95% CI: 0.8, 0.9
Whether youre on the pen, curious, or supporting someone who is, it breaks down myths, history, and the future of these treatments to foster meaningful conversations and connections.
After three months, all 10 patients of the study were able to stop taking prandial insulin.
Heres what that means for health care
